US EditionJohnson & Johnson MedTech Presents 3-Month Data from Omny-IRE Clinical Trial at 2025 Heart Rhythm Society Annual Meeting
- Johnson & Johnson MedTech announced initial Omny-IRE study results on April 25, 2025, in Irvine, California.
- The Omny-IRE study evaluates the investigational OMNYPULSE Platform for symptomatic paroxysmal atrial fibrillation treatment.
- This prospective pivotal study is currently underway across sites in Europe and Canada.
- Initial 3-month data showed 100% acute success and 84.5% durable isolation.
- These early findings indicate potential high acute effectiveness and a promising safety profile.
Insights by Ground AI
Does this summary seem wrong?
16 Articles
16 Articles
All
Left
2
Center
6
Right
Napa Valley Register+14 Reposted by 14 other sources
Johnson & Johnson MedTech Presents 3-Month Data from Omny-IRE Clinical Trial at 2025 Heart Rhythm Society Annual Meeting
Omny-IRE data demonstrated the investigational OMNYPULSE™ Platform achieved 100% acute success and 84.5% pulmonary vein isolation (PVI) durability at three months, with promising safety outcomes1
Johnson & Johnson and OMP present blueprint for supply chain transformation at Gartner Supply Chain Symposium/Xpo in Orlando
ORLANDO, Fla., April 25, 2025 (Ecnetnews.com) - OMP, a leading provider of supply chain planning solutions, invites attendees of the Gartner Supply Chain Symposium/Xpo™ 2025 to attend Johnson & Johnson's featured session. The presentation will highlight how the J&J Innovative Medicine division is transforming its supply chain to tackle global challenges using OMP's Unison Planning™.In
Coverage Details
Total News Sources16
Leaning Left2Leaning Right0Center6Last UpdatedBias Distribution75% Center
Bias Distribution
- 75% of the sources are Center
75% Center
L 25%
C 75%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
